Alpha-Enolase IgG

A positive result means your immune system is making antibodies against alpha-enolase. Alpha-enolase is a protein nearly every cell uses to turn sugar into energy. Your immune system can start noticing it when injured, infected, or abnormal cells expose it. That makes this a marker of immune response, not a diagnosis.

This is a research marker, not a routine autoimmune test. It cannot name a disease by itself. Read with symptoms and other antibodies, it may add weight to a few specific pictures: kidney involvement in lupus, lung scarring in scleroderma, ovarian endometrioma, or miscarriage risk in women who already carry thyroid antibodies.

What the Test Actually Detects

Most studies measure these antibodies in serum from a blood draw. The assays are not standardized. Labs may use native human alpha-enolase, yeast alpha-enolase, recombinant human protein, or a short fragment, so one lab's number may not match another's.

The test does not measure alpha-enolase itself. It measures an antibody, usually IgG, directed against that protein. IgG has subclasses. Several lupus nephritis studies point especially to IgG2.

Alpha-enolase is also written ENO1. It helps run the sugar-burning pathway called glycolysis. The protein also appears on some cell surfaces. There it helps bind plasminogen, one of the blood proteins used to break down clots.

Because the target protein is so common, these antibodies can appear whenever cells are damaged, infected, or dividing out of control and the usually hidden protein is shown to the immune system. That is why the same antibody turns up in conditions that otherwise have little in common.

Lupus and the Kidneys

In the first systemic autoimmune study, about 1 in 4 people with systemic lupus erythematosus carried this antibody, compared with about 1 in 16 healthy people. The antibody-positive lupus group stood out for kidney disease: 6 of the 9 antibody-positive lupus patients had active lupus nephritis. Lupus nephritis is kidney inflammation from lupus.

Later lupus nephritis work narrowed the signal. In diseased kidneys and matched serum, the dominant anti-alpha-enolase antibody was IgG2. Serum anti-alpha-enolase IgG2 was high in most lupus nephritis patients, roughly two-thirds or more across the reported cohorts, when judged against that study's control group, and it was largely absent in people with other glomerular kidney diseases. The kidney story is stronger than the general lupus story.

Scleroderma and Lung Scarring

One scleroderma study used both yeast alpha-enolase and recombinant human alpha-enolase assays. That is a reminder that not all assays are identical. The signal still lined up: roughly a quarter to a third of systemic sclerosis patients were positive, versus fewer controls. Antibody-positive patients had lower total lung capacity and lower oxygen transfer, and they more often carried anti-topoisomerase antibodies. That study tied the pattern to interstitial lung disease. In systemic sclerosis, that means lung scarring, and it is a major cause of disease-related death. The link is not settled, though: a later study found anti-alpha-enolase antibodies in nearly half of systemic sclerosis patients but no association with lung disease or any specific disease feature.

Endometriosis

Serum IgG against alpha-enolase was higher in women with ovarian endometrioma. Ovarian endometrioma is a cyst form of endometriosis. The useful number is the miss rate: the test caught about half of ovarian endometrioma cases and missed the rest. About four in five women without endometriosis were negative. In deep infiltrating endometriosis without ovarian cysts, alpha-enolase IgG was not a useful discriminator.

Pregnancy Loss with Thyroid Antibodies

Some women have thyroid antibodies but normal thyroid hormone levels, and they carry a higher risk of miscarriage that thyroid tests alone do not explain. In a matched study of these women, antibodies against a specific alpha-enolase fragment were independent risk factors for miscarriage, and the IgG2 subclass predicted pregnancy loss best. This is not the same as a whole-protein anti-alpha-enolase test. It is a fragment-specific version. The use is narrow and still early.

Pancreatic Cancer Prognosis

Pancreatic ductal adenocarcinoma is the usual type of pancreatic cancer. The evidence here is mixed and points in conflicting directions. In cancer, these antibodies usually target a phosphorylated (chemically modified) form of ENO1 rather than the native protein, and most work on that modified target has linked the antibodies to a better clinical outcome and better response to chemotherapy. One 470-person study reported the opposite, with higher circulating ENO1 autoantibody levels marking worse survival, but that finding runs against the larger body of evidence. Because cancer studies capture antibodies to modified ENO1 forms, none of this should be read like the autoimmune assay. Either way, this is prognosis in people who already have cancer, not screening. It has not been shown to catch pancreatic cancer early in someone healthy.

Early Liver Scarring

One liver fibrosis study used yeast alpha-enolase as the plate target. That is related to, but not identical to, human alpha-enolase. The antibody was more common in early, pre-cirrhotic fibrosis than in established cirrhosis or healthy controls. That suggests it may mark an active, earlier phase of injury rather than end-stage scarring.

The Citrullinated Cousin and Rheumatoid Arthritis

A related but different antibody causes a lot of confusion. In rheumatoid arthritis, the better-studied target is a chemically altered version of alpha-enolase called citrullinated alpha-enolase. Antibodies against it are called anti-CEP1. They have been tied to erosive joint damage and, in some studies, RA-associated lung disease. The lung link is disputed: a later prospective study found no association with new-onset RA lung disease once other risk factors were accounted for.

Anti-CEP1 is a different measurement from native alpha-enolase IgG. In one connective tissue disease study, anti-CEP1 appeared in about 1 in 10 lupus patients and 1 in 12 scleroderma patients. In that study, the lung disease link held in rheumatoid arthritis, not in lupus, Sjogren's, or scleroderma.

Why More Is Not Always Worse

In several autoimmune settings here, more antibody signals more disease activity. Blood cancers bend that rule. In a small plasma study, anti-ENO1 antibody levels followed a control > MDS > AML pattern, with AML clearly lower than controls. The antibody level did not predict survival in AML. This is not a universal high-bad, low-good test. The number only means something inside a specific clinical context.

Why One Reading Tells You Little

A single value is hard to act on for two reasons. First, the marker is not standardized: labs use different versions of the alpha-enolase protein, different sample dilutions, and different cutoffs. Second, the antibody can move with disease activity. In lupus nephritis, serum IgG2 against alpha-enolase fell over 12 months as patients were treated.

A same-assay trend is more useful than a borrowed cutoff. The useful question is not whether your number clears a universal bar. There is no universal bar. The question is whether it moves with the disease you are already tracking.

What a Positive Result Should Prompt

A positive result is a starting point for a workup, and what it should trigger depends on the rest of your picture. If you have joint, skin, or kidney symptoms, pair it with a standard autoimmune workup: antinuclear antibodies, anti-double-stranded DNA, complement proteins, kidney function, and a urine protein test if lupus is on the table. If you have breathlessness or a scleroderma diagnosis, lung function testing and imaging matter more than the antibody itself. If you have thyroid antibodies and recurrent miscarriage, pair this with thyroid antibody and thyroid hormone testing and discuss the pattern with a reproductive specialist.

Combinations are what count. This antibody plus active kidney signs plus lupus-specific antibodies is a very different situation from this antibody alone in someone with no symptoms. A rheumatologist, or a nephrologist if kidney findings show up, is the right person to weigh the pattern.

When the Number Can Mislead You

• Assay variation: different labs coat their plates with different versions of alpha-enolase, including human, yeast, or synthetic fragments. Compare only values from the same lab and same method.
• Cross-reactivity: antibodies raised against other proteins can bind alpha-enolase because parts of it resemble proteins from viruses and other organisms. A rotavirus-induced biliary atresia mouse model, with supporting infant serum data, found cross-reaction between anti-enolase antibodies and viral proteins.
• Healthy carriers: a small share of people with no known disease carry this antibody, so a low-level positive on its own is not proof of illness.
• The wrong cousin: a lab measuring citrullinated alpha-enolase, or anti-CEP1, is testing something different from native alpha-enolase IgG. Confirm which one was run before you interpret the result.